Abstract
Research into novel therapeutic strategies for schizophrenia with high efficacy and low side effects has been progressed in recent years. In the present study, anti-schizophrenia activities of 2-(dimethylamino)- and 2-(methylamino)- 7H-naphtho[1,2,3-de]quinolin-7-one derivatives (D1-D10) have been evaluated in ketamine-induced experimental schizophrenia model in mice. For this aim, experimental animals was submitted to ketamine intraperitoneal injection at 100 mg/kg/day. Then, D1-D10 were administrated intra-cerebroventricularly to mice and in next step, animals depressive-like behaviors have been examined by despair swimming test. The obtained results demonstrate that 7H-naphtho[1,2,3- de]quinolin-7-one derivatives, specifically D9, reduced depressive-like behaviors via the decrease of the immobility time and the increase of the swim and climb times. Overall, these results showed that these alkaloids have anti-schizophrenia efficacy and due to their low side effects, they can be used as a new strategy for the treatment of depressive symptoms of schizophrenia patients.
Keywords: Anti-schizophrenia, behavior, depressive-like, psychosis, ketamine, 7H-naphtho[1, 2, 3-de]quinolin-7-one.
Current Topics in Medicinal Chemistry
Title:Evaluation of the Antipsychotic Effects of 2-(dimethylamino)- and 2-(methylamino)-7H-naphtho[1,2,3-de]quinolin-7-one Derivatives in Experimental Model of Psychosis in Mice
Volume: 14 Issue: 2
Author(s): Akbar Hajizadeh Moghaddam, Eduardo Sobarzo-Sánchez, Seyed Fazel Nabavi, Maria Daglia and Seyed Mohammad Nabavi
Affiliation:
Keywords: Anti-schizophrenia, behavior, depressive-like, psychosis, ketamine, 7H-naphtho[1, 2, 3-de]quinolin-7-one.
Abstract: Research into novel therapeutic strategies for schizophrenia with high efficacy and low side effects has been progressed in recent years. In the present study, anti-schizophrenia activities of 2-(dimethylamino)- and 2-(methylamino)- 7H-naphtho[1,2,3-de]quinolin-7-one derivatives (D1-D10) have been evaluated in ketamine-induced experimental schizophrenia model in mice. For this aim, experimental animals was submitted to ketamine intraperitoneal injection at 100 mg/kg/day. Then, D1-D10 were administrated intra-cerebroventricularly to mice and in next step, animals depressive-like behaviors have been examined by despair swimming test. The obtained results demonstrate that 7H-naphtho[1,2,3- de]quinolin-7-one derivatives, specifically D9, reduced depressive-like behaviors via the decrease of the immobility time and the increase of the swim and climb times. Overall, these results showed that these alkaloids have anti-schizophrenia efficacy and due to their low side effects, they can be used as a new strategy for the treatment of depressive symptoms of schizophrenia patients.
Export Options
About this article
Cite this article as:
Moghaddam Hajizadeh Akbar, Sobarzo-Sánchez Eduardo, Nabavi Fazel Seyed, Daglia Maria and Nabavi Mohammad Seyed, Evaluation of the Antipsychotic Effects of 2-(dimethylamino)- and 2-(methylamino)-7H-naphtho[1,2,3-de]quinolin-7-one Derivatives in Experimental Model of Psychosis in Mice, Current Topics in Medicinal Chemistry 2014; 14 (2) . https://dx.doi.org/10.2174/1568026613666131213161443
DOI https://dx.doi.org/10.2174/1568026613666131213161443 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Minocycline Inhibits mTOR Signaling Activation and Alleviates Behavioral Deficits in the Wistar Rats with Acute Ischemia stroke
CNS & Neurological Disorders - Drug Targets Role of Kynurenines in the Central and Peripherial Nervous Systems
Current Neurovascular Research Melatonin Redox Activity. Its Potential Clinical Applications in Neurodegenerative Disorders
Current Topics in Medicinal Chemistry Therapeutic Efficacy of Selegiline in Neurodegenerative Disorders and Neurological Diseases
Current Drug Targets Mood and Anxiety Disorders in Breast Cancer: An Update
Current Psychiatry Reviews Extracellular Matrix in Atherosclerosis: Hyaluronan and Proteoglycans Insights
Current Medicinal Chemistry Current and Future Therapeutic Strategies for Parkinsons Disease
Current Pharmaceutical Design The Treatment of Behavioral and Psychological Symptoms of Dementia: Weighing Benefits and Risks
Current Alzheimer Research Going up in Smoke? A Review of nAChRs-based Treatment Strategies for Improving Cognition in Schizophrenia
Current Pharmaceutical Design Role of the 5-HT2C Receptor in Atypical Antipsychotics: Hero or Villain?
Current Medicinal Chemistry - Central Nervous System Agents Gene Therapy for Neurological Disorders: Challenges and Future Prospects for the Use of Growth Factors for the Treatment of Parkinsons Disease
Current Gene Therapy Peripheral and Central Glutamate Dyshomeostasis in Neurodegenerative Disorders
Current Neuropharmacology Do mtDNA Mutations Participate in the Pathogenesis of Sporadic Parkinsons Disease?
Current Genomics Applications of Nanotechnology in Diagnostics and Therapeutics of Alzheimer’s and Parkinson’s Disease
Current Drug Metabolism Cutting through the Complexities of mTOR for the Treatment of Stroke
Current Neurovascular Research Small Molecule Efflux Pump Inhibitors in Mycobacterium tuberculosis: A Rational Drug Design Perspective
Mini-Reviews in Medicinal Chemistry Liquid Chromatography-Mass Spectrometry Method for the Determination of Olanzapine in Human Plasma and Application to a Bioequivalence Study
Current Pharmaceutical Analysis The Genetic Variation of ARRB2 is Associated with Late-onset Alzheimer's Disease in Han Chinese
Current Alzheimer Research Amantadine, Apomorphine and Zolpidem in the Treatment of Disorders of Consciousness
Current Pharmaceutical Design Randomized Placebo-Controlled Trials of Omega-3 Polyunsaturated Fatty Acids in Psychiatric Disorders: A Review of the Current Literature
Current Drug Discovery Technologies